Intact 5-HT2A receptor exons and the adjoining intron regions in schizophrenia

被引:33
作者
Ishigaki, T
Xie, DW
Liu, JC
Nakamura, Y
Zhang, HY
Tani, K
Shimazu, Y
Chen, K
Shih, JC
Miyasato, K
Chara, K
Ohara, K
机构
[1] HAMAMATSU UNIV SCH MED, DEPT PSYCHIAT, HAMAMATSU, SHIZUOKA 43131, JAPAN
[2] UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL, LOS ANGELES, CA 90033 USA
[3] UNIV SO CALIF, SCH PHARM, DEPT TOXICOL, LOS ANGELES, CA 90033 USA
[4] SHANGHAI MED UNIV 2, DEPT PSYCHIAT, SHANGHAI, PEOPLES R CHINA
关键词
schizophrenia; 5-HT2A receptor; polymerase chain reaction; restriction fragment length polymorphism; single-strand conformation polymorphism; polymorphism;
D O I
10.1016/0893-133X(95)00143-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Genes that regulate serotonergic (5-HT) systems may underlie the etiology of schizophrenia. In this study the gene encoding the 5-HT2A receptor in schizophrenics and healthy controls was examined. First, we sequenced all exons and the flanking introns of the 5-HT2A receptor gene in 10 schizophrenics and 10 controls. The substitution of C for T at position 102, in exon 1, which had been reported by Warren et al. (1993), was confirmed. Restriction fragment length polymorphism (RFLP) analysis revealed Mo association between polymorphism and schizophrenia. There was no association between the polymorphism and subdiagnosis, family history, age of onset, amounts of antipsychotics, or positive and negative symptoms before or after medication. Other polymorphisms in the gene were screened in 100 schizophrenics by the single-strand conformation polymorphism method, but none was found. Our results suggest that an abnormality in the 5-HT(2A)receptor gene in schizophrenia is unlikely.
引用
收藏
页码:339 / 347
页数:9
相关论文
共 46 条
[1]   SEROTONIN-2 (5-HT2) RECEPTOR-BINDING IN THE FRONTAL-CORTEX OF SCHIZOPHRENIC-PATIENTS [J].
ARORA, RC ;
MELTZER, HY .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1991, 85 (01) :19-29
[2]   THE HUMAN 5-HT2 RECEPTOR IS ENCODED BY A MULTIPLE INTRON EXON GENE [J].
CHEN, K ;
YANG, W ;
GRIMSBY, J ;
SHIH, JC .
MOLECULAR BRAIN RESEARCH, 1992, 14 (1-2) :20-26
[3]   RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY [J].
CLAUS, A ;
BOLLEN, J ;
DECUYPER, H ;
ENEMAN, M ;
MALFROID, M ;
PEUSKENS, J ;
HEYLEN, S .
ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) :295-305
[4]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[5]   MOLECULAR PATHOLOGY OF SCHIZOPHRENIA - MORE THAN ONE DISEASE PROCESS [J].
CROW, TJ .
BRITISH MEDICAL JOURNAL, 1980, 280 (6207) :66-68
[7]   GLIAL CELL-SPECIFIC EXPRESSION OF THE SEROTONIN-2 RECEPTOR GENE - SELECTIVE REACTIVATION OF A REPRESSED PROMOTER [J].
DING, DM ;
TOTH, M ;
ZHOU, YZ ;
PARKS, C ;
HOFFMAN, BJ ;
SHENK, T .
MOLECULAR BRAIN RESEARCH, 1993, 20 (03) :181-191
[8]   RITANSERIN, A SELECTIVE 5-HT(2/1C) ANTAGONIST, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - A PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL [J].
DUINKERKE, SJ ;
BOTTER, PA ;
JANSEN, AAI ;
VANDONGEN, PAM ;
VANHAAFTEN, AJ ;
BOOM, AJ ;
VANLAARHOVEN, JHM ;
BUSARD, HLSM .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :451-455
[9]  
HALLMAYER J, 1992, ARCH GEN PSYCHIAT, V49, P216
[10]  
Hayashi K, 1991, PCR Methods Appl, V1, P34